CAR‑T cell therapy: a game‑changer in cancer treatment and beyond

• Kumar Utkarsh ^[2] ; Namita Srivastava ^[2] ; Sachin Kumar ^[2] ; Azhar Khan ^[3] ; Gunjan Dagar ^[4] ; Mayank Singh ^[4] ; Mukesh Kumar ^[5] ; Shabirul Haque ^[1]
  1. [1] Institute for Medical Research

     Institute for Medical Research

     Township of Durham, Estados Unidos

     
  2. [2] Department of Microbiology and Biotechnology, Shoolini University, Solan, Himachal Pradesh 173229, India
  3. [3] Faculty of Applied Science and Biotechnology, Shoolini University, Solan, Himachal Pradesh 173229, India
  4. [4] Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India
  5. [5] Department of Medical Oncology, Thomas Jeferson University, Philadelphia, PA 19107, USA

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 26, Nº. 6, 2024, págs. 1300-1318
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • In recent years, cancer has become one of the primary causes of mortality, approximately 10 million deaths worldwide each year. The most advanced, chimeric antigen receptor (CAR) T cell immunotherapy has turned out as a promising treatment for cancer. CAR-T cell therapy involves the genetic modifcation of T cells obtained from the patient's blood, and infusion back to the patients. CAR-T cell immunotherapy has led to a signifcant improvement in the remission rates of hematological cancers. CAR-T cell therapy presently limited to hematological cancers, there are ongoing eforts to develop additional CAR constructs such as bispecifc CAR, tandem CAR, inhibitory CAR, combined antigens, CRISPR gene-editing, and nanoparticle delivery. With these advancements, CAR-T cell therapy holds promise concerning potential to improve upon traditional cancer treatments such as chemotherapy and radiation while reducing associated toxicities. This review covers recent advances and advantages of CAR-T cell immunotherapy.